AnaptysBio, Inc. ANAB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 17.6%+107pp | 20.4%+146pp | -16.9%+241pp | -69.9%+463pp | -89.6%+617pp | |
| EBITDA margin | 17.8%+107pp | 20.7%+146pp | -16.6%+240pp | -69.5%+461pp | -89.1%+614pp | |
| Free cash flow margin | 1.9%+99.5pp | 8.4%+157pp | -85.8%+95.1pp | -104%+322pp | -97.6%+487pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.3× | 0.6×+0.4× | 0.4×+0.3× | 0.3×+0.3× | 0.3×+0.2× | |
| Liquidity | ||||||
| Current ratio | 7.6×-0.7× | 9.1×-0.4× | 8.7×-1.5× | 8.2×-0.9× | 8.2×-3.3× | |
| Quick ratio | 7.6×-0.7× | 9.1×-0.4× | 8.7×-1.5× | 8.2×-0.9× | 8.2×-3.3× | |
| Cash ratio | 6×+3.7× | 6.2×+3.5× | 2.9×-1.5× | 1.2×-0.5× | 2.2×+0.6× | |
| Leverage | ||||||
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.44-60.0% | $1.29-48.2% | -$1.01-135% | -$1.55-530% | $1.11-37.7% | |
| Valuation | ||||||
| Market capitalization | $1.59B+180% | $1.34B+233% | $856.53M-15.3% | $685.15M+0.1% | $570.1M-5.4% | |
| Enterprise value | $1.35B+176% | $1.1B+273% | $761.31M-9.0% | $655.95M+4.2% | $487.03M-14.0% | |
| Price / sales | 6.9×+1.8× | 5.7×+1.3× | 5.1×-12.6× | 5.6×-16.9× | 5.1×-21.2× | |
| EV / sales | 5.8×+1.4× | 4.7×+1.5× | 4.5×-10.1× | 5.3×-15.3× | 4.4×-20.3× | |
| Free cash flow yield | 0.3%+19.4pp | 1.5%+35.1pp | -17%-6.7pp | -18.7%+0.3pp | -19.1%+3.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do AnaptysBio, Inc.'s ratios come from?
- Every ratio is computed from AnaptysBio, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.